CBD and CBG Biomass Market size, Share, Growth, and Industry Analysis, By Type (CBD Biomass, CBG Biomass) By Application (Pharmaceuticals, Cosmetics, Wellness Products), and Regional Insights and Forecast to 2034

CBD AND CBG BIOMASS MARKET OVERVIEW

The global CBD and CBG Biomass Market size was USD 1.03 billion in 2025 and is projected to reach USD 3.00 billion by 2034, exhibiting a CAGR of 12.6% during the forecast period.

In an atmosphere of strong growth, demand is arising from the wellness, pharmaceutical, and cosmetic industries. CBD and CBG are psychoactive substances that are extracted from hemp biomass and possess therapeutic and anti-inflammatory effects. Increasing awareness worldwide about plant-based natural healing solutions has given momentum to these compounds as natural alternatives to synthetic drugs. The legalization of industrial hemp in several countries and an increased interest in natural wellness products have fueled the cultivation and processing of biomass. The CBD still leads the biggest market share in wellness and pain relief categories, but CBG-is gaining in relevance for being reputed as the "mother cannabinoid," thanks to its antibacterial and neuroprotective properties. Companies are heavily investing in organic cultivation opportunities, extraction methods, and understanding regulatory applications at an international quality level. Further growth is envisaged on clinical validity processes, indicating the emergence of new use cases and driving cross-sector adoption.

COVID-19 IMPACT

CBD and CBG Biomass Market Had a Positive Effect Due to Supply Disruptions Occurred During COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The CBD and CBG biomass market, in contrast, saw some benefits and some drawbacks during the COVID-19 pandemic. The cultivation, harvesting, and international trade of hemp biomass were in one word disrupted by supply-chain snarls and regulatory delays. A few growers confronted labor shortages or logistical inconveniences that became bottlenecks in biomass processing. On the other hand, the wellness boom triggered by the lockdowns created a parallel increase in demand for CBD and CBG-based products, especially those geared toward relief from anxiety, sleep issues, and immune support. Wellness product distribution began migrating through e-commerce channels, thus kick-starting the digitalization of the entire industry. The pandemic thus grew to favor the market, for there arose a demand for natural supplements that could ease stress and, in the process, enable better longevity prospects for the biomass market.

LATEST TRENDS

Rising Focus on Rare Cannabinoids and Genetic Innovation to Drive Market Growth

Thesis: One major trend in the CBD-CBG biomass industry is the increasing attention placed upon rare cannabinoids and strain-specific biomass culturing. Companies are utilizing modern genetics and breed approaches to increase cannabinoid yields and breed customized strains rich in CBG, CBC, and other less known compounds. Such innovations allow for diversification of product lines, particularly in high-margin pharmaceutical and therapeutic applications. Besides this, cultivation in greenhouses or indoors is being fine-tuned for high biomass potency and purity. Extraction methods are changing as well, with cryogenic and solventless extraction getting much attention for maintaining plant integrity. These new ways put a new definition to biomass valuations, keeping the market away from commodity-focused and toward quality-centric production.

CBD AND CBG BIOMASS MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into CBD Biomass, CBG Biomass:

• CBD Biomass: CBD biomass reigns over the market, owing to its massive use in wellness, pharmaceuticals, and personal care. Grown mainly from industrial hemp, CBD biomass has cannabidiol in high concentrations, which are extracted and further refined into oils, tinctures, and isolates. Increasing acceptance of the use of CBD for anxiety, pain relief, and inflammation continues to foster cultivation. Regulatory clarity-or perhaps the lack of it-in North America and Europe until recently put a dampener; now, however, large-scale producers are rapidly entering this scene, spawning a sprouting outlook toward organic and GMP-compliant production. CBD biomass is also a key ingredient in functional foods and nutraceuticals, thereby placing it at the core of the plant-based health economy.

• CBG Biomass: Since it is relatively newer, CBG biomass is now catching momentum because of its broad therapeutic spectrum. Due to antibacterial, anti-inflammatory, and neuroprotective properties, CBG has been under investigation for glaucoma, Huntington’s disease, and certain cancers. Usually, CBG is extracted from either young hemp plants or a few special low THC-varieties. For the low natural concentration of CBG, the price for its biomass is high, and special techniques are needed to cultivate it. Companies are investing in R&D to pursue greater CBG production per acre and reduce costs for producers. With the increasing consumer awareness and further research, CBG biomass is likely to earn a major place in the premium cannabinoid category.

By Application

Based on application, the global market can be categorized into Pharmaceuticals, Cosmetics, Wellness Products:

• Pharmaceuticals: Pharmaceuticals are a major end-user market for the CBD and CBG biomass, while research continues to investigate chronic pain, epilepsy, anxiety, and neurodegenerative diseases as potential areas of treatment. The success of GW with CBD-based drugs confirmed therapeutic claims for hemp substances and set into motion pharmaceutical companies investing in clinical trials and cannabinoid R&D. Facilities are analyzing CBD and CBG extracts for anti-inflammatory and anti-glutamate seizure potentials to be used in drugs. The demand for pharmaceutical-grade biomass has led growers to tighten their criteria for cultivation and offer traceability to it. Regulatory approvals continue to increase slowly, thus advancing cannabinoids into mainstream medicine.

• Cosmetics: CBD and CBG are famous within the cosmetics world industry because of their claimed benefits for skin-soothing, anti-aging, and antioxidant. Cannabinoid products have entered the world of skin care- creams, serums, and balms. CBG is becoming popular for its anti-inflammatory properties suited to sensitive or acne-prone skin. As consumer preference shifts toward clean, plant-based beauty, companies source biomass that is organic and has high cannabinoid content. The demand for full-spectrum and broad-spectrum extracts has gone into the creation of multi-cannabinoid cosmetic blends. With a rising demand for wellness-based glamour across the globe, cannabinoid biomass is poised to become a star in the cosmetics value chain.

• Musical Instrument: Wellness products, tinctures, edibles, topicals, and beverages are considered the most commercially dynamic application segments for CBD and CBG biomass. These products mostly reach a health-focused consumer base aimed at remedying their stress, insomnia, or chronic pain. CBD is popularly advertised as calming, while CBG is carving out a reputation as an anti-counterfeiting agent and immune booster. To its credit, probably the rise of direct-to-consumer brands and e-commerce avenues made wellness viable worldwide. In the spirit of transparency, sourcing good-quality biomass with third-party certification is becoming consistent practice for companies. As consumers uplift their knowledge and awareness, cannabinoid wellness supplements are establishing themselves as mainstream components in holistic health practices.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Legalization and Regulatory Clarity Accelerating Market Expansion to Boost the Market

With the formation of regulatory clarity and the steady wave of hemp legalization in some of the major markets, the market has been given a primary impetus for CBD and CBG Biomass Market Growth in hemp biomass CBD and CBG industries. Countries like the US, Canada, Germany, and Australia have created legal frameworks allowing industrial hemp farming, production, and extraction of cannabinoids for commercial purposes. These developed legal supports have birthed investment in agriculture, processing infrastructure, and retail distribution. With more jurisdictions remodeling their cannabis-related legislations, companies can tap into international markets while also operating within a higher level of compliance. Such regulatory support instills consumer confidence, highly sought after in any wellness-based industry. This legal momentum acts as the foundation on which the market grows and stabilizes.

Rising Demand for Natural and Plant-Based Therapeutics to Expand the Market

The consumer inclination toward natural remedies and Ayurveda-based remedies is expanding the CBD and CBG biomass market. Cannabinoids thus become a compelling alternative as suspicion grows concerning synthetic pharmaceuticals and their side effects. Their usage encompasses mental wellness, chronic pain, skincare, and the immune system. Particularly, millennials and Gen Z consumers prefer botanical solutions in line with sustainable organic living. Retailers and e-commerce platforms have seized this trend by providing numerous possibilities of cannabinoid-infused products. This shift toward holistic health stands to increase demand for ethically sourced and high-quality biomass in various verticals.

Restraining Factor

Lack of Standardization and Regulatory Disparities Hinder Global Trade to Potentially Impede Market Growth

The lack of uniformity regarding regulations and quality standards is one of the major hurdles in the CBD/CBG biomass market. Various countries impose different rules concerning THC limits, cannabinoid labeling, or testing regimen, impeding international trade and compliance. Producers are often put in a bind and forced to accommodate regional requirements at higher costs and operational complications. On the other hand, the lack of harmonized standards further confuses the consumer and limits branding across borders. International regulatory bodies, upon the implementation of such a framework, will cement the ability of companies to export biomass and develop standardized supply chains. Considering the present regulatory turmoil, much potential remains untouched by these products on the open market.

Opportunity

Expansion of Pharmaceutical and Clinical Research into New Therapeutic Areas to Create Opportunity for The Product in The Market

The steadily growing clinical research into the therapeutic effects of CBD and CBG is a very exciting opportunity. Research institutions and biotech companies are examining their usefulness for anything from neurodegenerative disorders to cancer. As scientific evidence becomes increasingly incontrovertible, the biomass market will likewise reap the benefits of elevated demand from pharmaceutical concerns. Biomass grown for maximum cannabinoid yield and medical-grade purity will, of course, be in need. Accelerated innovation through collaborative ventures between growers and research laboratories could potentially draw in funds from governmental or private sources. Pharma companies entering the cannabinoid field would mean a big scale increase in biomass consumption and credibility.

Challenge

Ensuring Supply Chain Transparency and Quality Consistency Could Be a Potential Challenge for Consumers

One of the big challenges facing the CBD and CBG biomass industries is quality maintenance and a full supply chain traceability. There are various factors affecting biomass quality depending on culture, harvesting, and extraction standards. The quality of end products is reduced by inconsistencies in cannabinoid contents, pesticide contamination, heavy metals, improper post-harvest treatment, etc. As the regulators and consumers demand transparency, companies must accordingly set up stringent controls over quality, third-party testing, and track and trace systems. Small-scale growers face difficulty in meeting the standards owing to their complete lack of resourceful means. In building a solid, transparent supply chain lies market trust and long-term growth.

CBD AND CBG BIOMASS MARKET REGIONAL INSIGHTS

• North America

North America holds the dominant CBD and CBG Biomass Market share, given legislation, agricultural practices, and strong consumer demand. Both the United States CBD and CBG Biomass Market and Canada market allow the commercial cultivation of industrial hemp; hence, both countries have built legal frameworks for the extraction, manufacture, and sale of the products. High output of biomass is supported by large-scale farms, research institutes, and processing plants. Consumers in this region tend to be open to cannabinoid wellness products marketed for stress relief and sleep support. In addition, North American companies were among the first to invest in CBG-specific strains and high-yield cultivation technologies, promoting the region to be a leading and innovative center.

• Europe

With rising health consciousness and regulatory changes, the CBD and CBG biomass market in Europe maintains its steady flow of travelers. Germany, the UK, and the Netherlands are major markets wherein medicinal cannabis enjoys a lawful status with an increasing sway of health applications. Yet, with EU-regulations being diverse, individual countries begin to embrace harmonized standards, side-by-side, of EFSA and EMA. Consumers are interested in biomass that is organic and locally sourced; thus, the demand for traceable and compliant supply chains keeps growing. Innovations in product formulations and clinical research boost biomass consumption. The rigorously defined safety and quality norms of the region have come forth to be a testament for globally followed standards.

• Asia

Asia is an emerging frontier for CBD and CBG biomass. Recently, countries such as South Korea, Japan, and Thailand have established legal regimes allowing industrial hemp and cannabinoid research. China, already one of the major producers of hemp fiber, is also starting to look at cannabinoid extraction and biomass exportations. The wellness and cosmetic industries in the region hold high potential for cannabinoid-product businesses. Yet, fierce regulatory ambiguity and cultural stigma slow down the adoption speed. However, increased awareness of plant-based health solutions and an acceleration in investment in the hemp infrastructure indicate that the biomass market in Asia is set for exponential growth in the coming years.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market Through Innovation and Market Expansion

Key players in the CBD and CBG biomass market shape the sector through strategic cultivation, research, and product innovation. Canopy Growth Corporation, Aurora Cannabis, and Tilray set up vertically integrated operations to assure quality and scalability of the biomass. GW Pharmaceuticals was a forerunner in medical application of clinical-grade CBD. In the U.S., companies such as Charlotte's Web and CV Sciences focus on wellness and dietary products, whereas Folium Biosciences heads cannabinoid extraction and supply. These companies employ a global approach, collaborate with health-care providers on R&D of rare cannabinoids, and invest in R&D of rare cannabinoids to maintain their competitive edge and meet demand.

List Of Top Cbd And Cbg Biomass Companies

• Canopy Growth Corporation (Canada)
• Aurora Cannabis Inc. (Canada)
• Tilray (Canada)
• Cronos Group (Canada)
• GW Pharmaceuticals (U.K.)
• Charlotte's Web Holdings, Inc. (U.S.)
• CV Sciences, Inc. (U.S.)
• Medical Marijuana, Inc. (U.S.)
• Elixinol Global Limited (Australia)
• Folium Biosciences (U.S.)

KEY INDUSTRY DEVELOPMENT

June 2025: Top cannabinoid producers such as Tilray, Cronos Group, and Elixinol Global Limited have announced a multi-national collaboration to create a global hemp genetics library with the purpose of maximizing CBD and CBG yields. The library shall ensure strain profiles are standard; maximize cannabinoid potency; and reduce the cost of cultivation. Meanwhile, Charlotte’s Web and Folium Biosciences are also defining and developing a blockchain-based traceability platform that follows the origin and quality of biomass all the way through. All these endeavors denote a maturing market that values transparency, efficiency, and innovation. This shall, therefore, spur international trade and foster consumer confidence in biomass-based wellbeing and pharmaceutical products.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.